Ipratropium is an anticholinergic drug with a strong bronchial smooth muscle relaxing effect. In chronic obstructive pulmonary disease, it also has a calming effect on asthma, which is more pronounced and has a faster onset and longer duration of action. It also has the effect of controlling the secretion of mucus glands and improving the movement of cilia, which can reduce the obstruction of sputum to improve the ventilation. The reduction of sputum also reduces the bronchospasm caused by bronchial irritation. Compared to adrenergic receptor stimulants, it has fewer cardiovascular side effects and is more effective in regulating sputum volume. However, ipratropium can only temporarily improve the bronchospasm and has little effect on the treatment of the primary disease. The treatment of the primary disease is the most important.